Aims: This study aimed to identify differences in the implementation of cognitive activities and instrumental activities of daily living (IADLs) between healthy individuals and subjects with mild cognitive impairment (MCI).
Methods: The study included 2,498 cognitively healthy subjects (mean age, 71.2 ± 5.1 years) and 809 MCI subjects (mean age, 71.8 ± 5.4 years). The subjects were interviewed regarding their participation in cognitive activities and the implementation of IADLs.
Results: We found a significant association between participation in any cognitive activities (p < 0.001), using a bus or a train (p < 0.001), and MCI. After adjusting for covariates, cognitive activity of any type remained significantly associated with MCI (p < 0.005) but not with the implementation of IADLs.
Conclusions: Our study revealed that greater participation in cognitive activity was associated with lower odds of MCI. Participation in cognitive activities may reflect differences between healthy and MCI subjects. To clarify the causal relationship between cognitive activities and MCI, further studies are required.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3843918 | PMC |
| http://dx.doi.org/10.1159/000355553 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development and evaluation of a free e-learning program on dementia risk reduction for the general public: A pre-post study.
J Alzheimers Dis
January 2025
Alzheimer Centrum Limburg, Mental Health and Neuroscience Research Institute (MHeNs), Department of Psychiatry and Neuropsychology, Maastricht University, Maastricht, Netherlands.
Background: There is consistent evidence for the contribution of modifiable risk factors to dementia risk, offering opportunities for primary prevention. Yet, most individuals are unaware of these opportunities.
Objective: To investigate whether online education about dementia risk reduction may be a low-level means to increase knowledge and support self-management of modifiable dementia risk factors.
SMOC2 promotes microglia activity and neuroinflammation in Alzheimer's disease.
J Alzheimers Dis
January 2025
Department of Vascular Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Background: Alzheimer's disease (AD), the leading cause of dementia, is characterized by cognitive decline and the accumulation of amyloid-β (Aβ). It affects millions, with numbers expected to double by 2050. SMOC2, implicated in inflammation and fibrosis, may play a role in AD pathogenesis, particularly in microglial cell function, offering a potential therapeutic target.
View Article and Find Full Text PDFThe canine blood-brain barrier in health and disease: focus on brain protection.
Vet Q
December 2025
Department of Physiology, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada.
This review examines the role of the canine blood-brain barrier (BBB) in health and disease, focusing on the impact of the multidrug resistance (MDR) transporter P-glycoprotein (P-gp) encoded by the gene. The BBB is critical in maintaining central nervous system homeostasis and brain protection against xenobiotics and environmental drugs that may be circulating in the blood stream. We revise key anatomical, histological and functional aspects of the canine BBB and examine the role of the gene mutation in specific dog breeds that exhibit reduced P-gp activity and disrupted drug brain pharmacokinetics.
View Article and Find Full Text PDFAnti-neuroinflammatory and Neuroprotective Effects of T-006 on Alzheimer's Disease Models by Modulating TLR4-Mediated MyD88/ NF-κB Signaling.
CNS Neurol Disord Drug Targets
January 2025
School of Medicine, Foshan University, Foshan, 528000, China.
Introduction: Neuroinflammation derived from the activation of the microglia is considered a vital pathogenic factor of Alzheimer's Disease (AD). T-006, a tetramethylpyrazine derivative, has been found to alleviate cognitive deficits via inhibiting tau expression and phosphorylation in AD transgenic mouse models. Recently, T-006 has been proven to dramatically decrease the levels of total Amyloid β (Aβ) peptide and Glial Fibrillary Acidic Protein (GFAP) and suppress the expression of ionized calcium binding adaptor molecule-1 (Iba-1) in APP/PS1 mice.
View Article and Find Full Text PDFBody composition differences in older adults with and without Alzheimer's disease: A systematic review and meta-analysis of observational studies.
J Alzheimers Dis
January 2025
Department of Medical Sciences, Minas Gerais State University, Minas Gerais, Brazil.
Background: Research on body composition and fat distribution in Alzheimer's disease (AD) has presented conflicting findings.
Objective: Compare body composition and anthropometric measurements in older adults with and without AD.
Methods: A systematic review and meta-analysis were conducted following Cochrane guidelines and PRISMA standards.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!